Skip to main content
BBOT
NASDAQ Life Sciences

FDA授予BBOT的胰腺癌药物BBO-11818快速通道指定

feedReported by Reuters
Sentiment info
Positive
Importance info
8
Price
$9.8
Mkt Cap
$741.104M
52W Low
$8.08
52W High
$14.87
Market data snapshot near publication time

summarizeSummary

BridgeBio肿瘤治疗公司（BBOT）获得了美国FDA对其实验性药物BBO-11818的快速通道指定，用于治疗晚期KRAS突变性胰腺导管腺癌。这一指定是一个重要的积极发展，因为它可以加速治疗严重疾病和未满足的医疗需求的疗法的开发和审查。对于像BBOT这样的临床阶段生物技术公司来说，这种监管加速可以大大缩短上市时间，可能提高药物的价值和公司的整体估值。这一消息也对其母公司BridgeBio制药公司（BBIO）产生了积极影响。投资者现在将密切关注BBO-11818的最新一期临床数据，该数据预计将在2026年下半年公布。

在该公告发布时，BBOT的交易价格为$9.80，交易所为NASDAQ，所属行业为Life Sciences，市值约为$7.4亿。 52周交易区间为$8.08至$14.87。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed BBOT - Latest Insights

BBOT
Apr 22, 2026, 5:56 PM EDT
Filing Type: 424B3
Importance Score:
8
BridgeBio Oncology Therapeutics Announces Major Executive Leadership Overhaul
Sentiment: Negative
View Wiseek Article
BBOT
Apr 22, 2026, 5:31 PM EDT
Filing Type: 8-K
Importance Score:
8
BridgeBio Oncology Therapeutics Announces Comprehensive Executive Leadership Restructuring
Sentiment: Neutral
View Wiseek Article
BBOT
Apr 22, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
BBOT's Pan-KRAS Inhibitor BBO-11818 Shows Robust Anti-Tumor Activity in Preclinical Models
Sentiment: Positive
View Wiseek Article
BBOT
Apr 20, 2026, 5:58 PM EDT
Source: Reuters
Importance Score:
8
FDA Grants Fast Track Designation to BBOT's Pancreatic Cancer Drug BBO-11818
Sentiment: Positive
View Wiseek Article
BBOT
Mar 06, 2026, 10:07 AM EST
Source: GlobeNewswire
Importance Score:
8
Potent PanKRAS Inhibitor BBO-11818 Preclinical Data Published in Cancer Discovery
Sentiment: Positive
View Wiseek Article
BBOT
Mar 05, 2026, 4:40 PM EST
Filing Type: 10-K
Importance Score:
9
BridgeBio Oncology Therapeutics Reports Strong Clinical Data for Lead Programs and Extended Cash Runway
Sentiment: Positive
View Wiseek Article
BBOT
Mar 05, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
BBOT Drug Achieves First Monotherapy PanKRAS Response in Pancreatic Cancer; Positive Clinical Data & 2028 Cash Runway
Sentiment: Positive
View Wiseek Article
BBOT
Jan 07, 2026, 7:15 AM EST
Filing Type: 424B3
Importance Score:
9
BridgeBio Oncology Therapeutics Reports Positive Clinical Data Across Three Oncology Pipeline Programs
Sentiment: Positive
View Wiseek Article
BBOT
Jan 07, 2026, 7:12 AM EST
Filing Type: 424B3
Importance Score:
8
BridgeBio Oncology Therapeutics Registers Over 63M Shares for Resale, Discloses Material Weakness in Controls
Sentiment: Negative
View Wiseek Article
BBOT
Jan 07, 2026, 7:09 AM EST
Filing Type: 8-K
Importance Score:
8
BridgeBio Oncology Reports Strong Clinical Data for Three RAS/PI3K Alpha Pipeline Programs
Sentiment: Positive
View Wiseek Article